X-ray Source

Literature Library

The versatile Xoft® Axxent® Electronic Brachytherapy (eBx®) System® utilizes breakthrough electronic brachytherapy technology to provide expanded treatment options for a range of cancers. With the Xoft System, highly focused therapeutic radiation of the disease target is possible in a minimally shielded setting, while sparing surrounding healthy tissue.

The Xoft System utilizes a proprietary, miniaturized Axxent x-ray source to apply radiation directly to the tumor site. The isotope-free x-ray source allows the delivery of high dose rate, low energy radiation treatment in virtually any clinical setting with minimal shielding.

The fast dose fall-off of the 50 kV source minimizes exposure to adjacent healthy tissues and organs and allows medical personnel to remain in the room with the patient.

Combined with the comprehensive capabilities of the Xoft System, the x-ray source offers an attractive option to physicians and patients for improved flexibility, precision and personalization in the targeted treatment of cancer.

The Xoft System is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer and gynecological cancers. Indications currently under investigation include prostate, pancreatic, colorectal and brain cancers.

Clinical Data

Support

Share

Contact Us

Sales & Services

+1 877 963 8327 toll free

CONNECT

©2018 Xoft®, a subsidiary of iCAD, Inc. All rights reserved. Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc.  Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.

The versatile Xoft® Axxent® Electronic Brachytherapy (eBx®) System® utilizes breakthrough electronic brachytherapy technology to provide expanded treatment options for a range of cancers. With the Xoft System, highly focused therapeutic radiation of the disease target is possible in a minimally shielded setting, while sparing surrounding healthy tissue.